Generic Name and Formulations:
Ofloxacin 0.3%; oph. soln; contains benzalkonium chloride.
Indications for OCUFLOX:
Susceptible infections of the conjuctiva and corneal ulcer.
Adults and Children:
<1yr: not recommended. ≥1yr: Conjunctivitis: 1–2 drops every 2–4 hrs for 2 days, then 4 times daily for 5 more days. Corneal ulcer: 1–2 drops every 30 minutes while awake and at 4 hrs & 6 hrs after retiring for sleep for 2 days, then 1–2 drops every 1 hr while awake for days 3 through 7–9, then 1–2 drops 4 times daily through treatment completion.
Discontinue if superinfection or hypersensitivity occurs. Pregnancy (Cat.C). Nursing mothers: not recommended.
Possible potentiation of theophylline, caffeine, oral anticoagulants, cyclosporine if systemic absorption occurs.
Superinfection, photophobia, lacrimation, transient local reactions including burning, stinging, redness, itching, dry eye; anaphylaxis, Stevens-Johnson syndrome (rare).
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma